^
Association details:
| Biomarker: | BRCA wild-type |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) + ZEN-3694 (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1b/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
Published date:
05/26/2022
Excerpt:
Ph 2 portion of the trial met its primary endpoint with a CBR of 30% (11/37). For the Ph 1b/2 trial, investgator assessed ORR was 22% (11/50), including 2 CR, CBR was 35% (18/51) and the median DOR was 24 weeks. For the subset of TNBC at diagnosis patients (no history of HR+ disease), ORR was 32% (11/34), and CBR was 44% (15/34). Combination of ZEN-3694 and talazoparib demonstrated anti-cancer activity in pretreated mTNBC WT gBRCA1/2 patients.
DOI:
10.1200/JCO.2022.40.16_suppl.1023
Trial ID:
